Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 407 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR ESMO Shares Recommendations to Support Cancer Research and Clinical Trials in... May 28, 2026 Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 July 6, 2026 Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer July 5, 2022 PD1 and LAG3 Inhibition Plus Chemoradiotherapy in the Neoadjuvant Setting for... March 28, 2024 Load more HOT NEWS FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma ¿El azúcar provoca cáncer? How I Took Charge of My Cancer Care and Found a... New on NCI’s Websites for March 2021
